GSK2190915 Moderate to Severe Asthma Study

Summary

A randomised, double-blind, placebo-controlled, parallel group study to evaluate the effect of treatment with GSK2190915, a FLAP inhibitor, as add-on to current inhaled corticosteroid therapy in patients with moderate to severe asthma with elevated sputum neutrophils.

Timeline

Start

2009-06-26

Primary completion

2010-06-02

Completion

2010-06-02

Drugs

Indications